Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer

Ana Barat, Dominiek Smeets, Bruce Moran, Wu Zhang, Shu Cao, Sudipto Das, Rut Klinger, Johannes Betge, Verena Murphy, Orna Bacon, Elaine W. Kay, Nicole C.T. Van Grieken, Henk M.W. Verheul, Timo Gaiser, Nadine Schulte, Matthias P. Ebert, Bozena Fender, Bryan T. Hennessy, Deborah A. McNamara, Darran O’ConnorWilliam M. Gallagher, Chiara Cremolini, Fotios Loupakis, Aparna Parikh, Christoph Mancao, Bauke Ylstra, Diether Lambrechts, Heinz Josef Lenz, Annette T. Byrne, Jochen H.M. Prehn

Research output: Contribution to journalArticlepeer-review

Abstract

Chemotherapy combined with the angiogenesis inhibitor bevacizumab (BVZ) is approved as a first-line treatment in metastatic colorectal cancer (mCRC). Limited clinical benefit underpins the need for improved understanding of resistance mechanisms and the elucidation of novel predictive biomarkers. We assessed germline single-nucleotide polymorphisms (SNPs) in 180 mCRC patients (Angiopredict [APD] cohort) treated with combined BVZ + chemotherapy and investigated previously reported predictive SNPs. We further employed a machine learning approach to identify novel associations. In the APD cohort IL8 rs4073 any A carriers, compared to TT carriers, were associated with worse progression-free survival (PFS) (HR = 1.51, 95% CI:1.03–2.22, p-value = 0.037) and TBK1 rs7486100 TT carriers, compared to any A carriers, were associated with worse PFS in KRAS wild-type (wt) patients (HR = 1.94, 95% CI:1.04–3.61, p-value = 0.037), replicating previous findings. Machine learning identified novel associations in genes encoding the inflammasome protein NLRP1 and the ER protein Sarcalumenin (SRL). A negative association between PFS and carriers of any A at NLRP1 rs12150220 and AA for SRL rs13334970 in APD KRAS wild-type patients (HR = 4.44, 95% CI:1.23–16.13, p-value = 0.005), which validated in two independent clinical cohorts involving BVZ, MAVERICC and TRIBE. Our findings highlight a key role for inflammation and ER signalling underpinning BVZ + chemotherapy responsiveness.

Original languageEnglish
Article number9778
Number of pages12
JournalScientific Reports
Volume10
Issue number1
DOIs
Publication statusPublished - Dec 1 2020

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer'. Together they form a unique fingerprint.

Cite this